Ad
related to: medication to improve ejection fraction
Search results
Results From The WOW.Com Content Network
Sacubitril/valsartan can be used instead of an ACE inhibitor or an angiotensin receptor blocker in people with heart failure and a reduced left ventricular ejection fraction (LVEF), [17] [9] alongside other standard therapies (e.g. beta-blockers) for heart failure.
The RALES trial [30] showed that the addition of spironolactone can improve mortality, particularly in severe cardiomyopathy (ejection fraction less than 25%.) The related medication eplerenone was shown in the EPHESUS trial [ 31 ] to have a similar effect, and it is specifically labelled for use in decompensated heart failure complicating ...
Given the selective decrease in rate without loss of contractility, ivabradine may prove efficacious for treatment of congestive heart failure with reduced ejection fraction. Ivabradine binds to HCN4 receptors (potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4), utilizing Y506, F509 and I510 residues.
Heart failure, particularly with reduced ejection fraction (HFrEF), is a major cause of morbidity and mortality worldwide. Aldosterone, a hormone that promotes sodium retention and potassium excretion, plays a significant role in the pathophysiology of heart failure by contributing to fluid overload, myocardial fibrosis, and vascular damage.
Soluble guanylate cyclase (sGC) stimulators are a class of drugs developed to treat heart failure, pulmonary hypertension, and other diseases. The first-in-class medication was riociguat, approved in 2013 for pulmonary hypertension. [1] [2] They have also been investigated for hypertension, systemic sclerosis, and sickle cell disease. [3] [1]
Heart failure is categorized by a measurement known as ejection fraction. Ejection fraction is the amount of blood that the left ventricle of your heart pumps out each time it contracts.
Beta blockers counter this inappropriately high sympathetic activity, eventually leading to an improved ejection fraction, despite an initial reduction in ejection fraction. [citation needed] Trials have shown beta blockers reduce the absolute risk of death by 4.5% over a 13-month period.
Tirzepatide has demonstrated significant benefits in obese patients with a common type of heart failure, preserved ejection fraction (HFpEF) in a phase III trial. [ 25 ] [ 26 ] Over two years, tirzepatide reduced the risk of major complications, including urgent heart failure visits, hospitalizations, increased diuretic treatment, and ...
Ad
related to: medication to improve ejection fraction